ArticleMolecular pain
Cimifugin alleviates chronic inflammatory pain by inhibiting neuroinflammation and restoring synaptic function: A network pharmacology and in vivo study.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundChronic inflammatory pain has a high incidence, and existing drugs have side effects. The natural product Cimifugin has anti-inflammatory and analgesic potential, but its role and mechanism in treating chronic inflammatory pain remain unclear. This study aims to explore the potential targets, signaling pathways, and in vivo mechanism of Cimifugin in the treatment of chronic inflammatory pain.MethodsNetwork pharmacology was used to predict the potential targets and related pathways of Cimifugin. A mouse model of chronic inflammatory pain induced by complete Freund's adjuvant (CFA) was established. Behavioral tests (mechanical/thermal hyperalgesia, elevated plus maze) were conducted to evaluate pain sensation and anxiety-like behaviors. ELISA was used to detect inflammatory factors (IL-1β, IL-6, TNF-α). Western blot was employed to analyze synaptic functional proteins. HPLC-MS/MS was used to verify Cimifugin's ability to cross the blood-brain barrier.ResultsNetwork pharmacology analysis predicted that the 64 cross-targets of Cimifugin and chronic inflammatory pain are enriched in pathways such as MAPK and PI3K-Akt. Animal experiments showed that Cimifugin dose-dependently increased pain thresholds, reduced paw swelling, improved anxiety-like behaviors, decreased inflammatory factor levels, reversed abnormal expression of synaptic functional proteins, and could cross the blood-brain barrier.ConclusionCimifugin alleviates chronic inflammatory pain and related behavioral abnormalities, an effect associated with inhibition of inflammatory responses and restoration of synaptic protein expression. These findings suggest a multi-target, multi-pathway mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.